GI Innovation, Inc. (KOSDAQ:358570)
11,820
+220 (1.90%)
Jun 10, 2026, 3:30 PM KST
GI Innovation Revenue
GI Innovation had revenue of 5.63B KRW in the twelve months ending March 31, 2026, up 2,550.37% year-over-year. In the year 2025, GI Innovation had annual revenue of 5.84B with 23,943.39% growth.
Revenue (ttm)
5.63B
Revenue Growth
+2,550.37%
P/S Ratio
135.02
Revenue / Employee
n/a
Employees
n/a
Market Cap
759.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.84B | 5.81B | 23,943.39% |
| Dec 31, 2024 | 24.28M | -5.29B | -99.54% |
| Dec 31, 2023 | 5.32B | 1.82B | 51.97% |
| Dec 31, 2022 | 3.50B | -2.10B | -37.50% |
| Dec 31, 2021 | 5.60B | -5.42B | -49.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.29T |
| Medy-Tox | 244.02B |
| BINEX | 164.00B |
| MEDIPOST | 73.90B |
| Onconic Therapeutics | 67.20B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |